Jason K. Hou
Advanced in Anal Fissure

Dr. Jason K. Hou

Gastroenterology
7200 Cambridge St, Ste 8B-1, 
Houston, TX 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth
Advanced in Anal Fissure
7200 Cambridge St, Ste 8B-1, 
Houston, TX 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Jason Hou, MD, is dedicated to delivering high-quality, compassionate care to Houston and nearby communities. Jason Hou specializes in Gastroenterology and works at BCM Gastroenterology. To make an appointment, please call (713) 798-0950. To review all accepted insurance carriers, please visit: https://www.stlukeshealth.org/patients-visitors/patients/billing-insurance/insurances-accepted.

Dr. Hou is rated as an Advanced provider by MediFind in the treatment of Anal Fissure. His top areas of expertise are Viral Gastroenteritis, Crohn's Disease, Colitis, Colonoscopy, and Endoscopy.

His clinical research consists of co-authoring 103 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Anal Fissure.

Graduate Institution
Northwestern University Feinberg School Of Medicine
Specialties
Gastroenterology
Licenses
Internal Medicine in TX
Hospital Affiliations
Baylor St. Luke's Medical Center - Houston, TX
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Community Health
  • EPO
  • HMO
Community Health Choice
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Superior Health Plan
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
Trustmark
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 9 Less Insurance Carriers -

Locations

Baylor College of Medicine - Gastroenterology
7200 Cambridge St, Ste 8B-1, Houston, TX 77030

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

Multi-Center African-American Inflammatory Bowel Disease Study (MAAIS)
Multi-Center African-American Inflammatory Bowel Disease Study (MAAIS)
Enrollment Status: Recruiting
Publish Date: November 05, 2025
A Phase 3, Multicenter, Open-Label Extension Study to Evaluate the Long Term Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis LUCENT 3
A Phase 3, Multicenter, Open-Label Extension Study to Evaluate the Long Term Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis LUCENT 3
Enrollment Status: Active_not_recruiting
Publish Date: November 24, 2025
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 2)
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 2)
Enrollment Status: Completed
Publish Date: October 14, 2025
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)
Enrollment Status: Completed
Publish Date: May 31, 2025
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active- Controlled, Treat-Through Study to Evaluate the Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Crohn's Disease
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active- Controlled, Treat-Through Study to Evaluate the Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Crohn's Disease
Enrollment Status: Completed
Publish Date: December 27, 2024
Intervention Type: Drug
Study Drugs: Mirikizumab, Ustekinumab
Study Phase: Phase 3
Efficacy and Safety of ALTB-168 in Patients With Moderate to Severe Active, Anti-TNF Alpha and/or Anti-integrin Refractory Ulcerative Colitis: a 26-week, Open-label, Multi-center, Phase II Proof of Principle Trial
Efficacy and Safety of ALTB-168 in Patients With Moderate to Severe Active, Anti-TNF Alpha and/or Anti-integrin Refractory Ulcerative Colitis: a 26-week, Open-label, Multi-center, Phase II Proof of Principle Trial
Enrollment Status: Terminated
Publish Date: January 05, 2024
Intervention Type: Biological
Study Phase: Phase 2
A Randomized, Double Blind, Placebo-controlled, Multicenter, Parallel Group Study to Assess the Efficacy and Safety of Fixed-dose Combination RHB-104 in Subjects With Moderately to Severely Active Crohn's Disease
A Randomized, Double Blind, Placebo-controlled, Multicenter, Parallel Group Study to Assess the Efficacy and Safety of Fixed-dose Combination RHB-104 in Subjects With Moderately to Severely Active Crohn's Disease
Enrollment Status: Completed
Publish Date: December 08, 2020
Intervention Type: Drug
Study Phase: Phase 3
A Phase 2, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Study of LY3074828 in Subjects With Moderate to Severe Ulcerative Colitis
A Phase 2, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Study of LY3074828 in Subjects With Moderate to Severe Ulcerative Colitis
Enrollment Status: Completed
Publish Date: June 17, 2020
Intervention Type: Drug
Study Phase: Phase 2
View 7 Less Clinical Trials

103 Total Publications

Pharmacologic activation of HNF4α/γ Restores Epithelial Barrier Function in Crohn's disease.
Pharmacologic activation of HNF4α/γ Restores Epithelial Barrier Function in Crohn's disease.
Journal: bioRxiv : the preprint server for biology
Published: November 24, 2025
Similar Doctors
Advanced in Anal Fissure
Dr. Ryan Goldstein
Gastroenterology
Advanced in Anal Fissure
Dr. Ryan Goldstein
Gastroenterology

Gold Diagnostics Corp

6633 Bellfort St, 
Houston, TX 
 (5.4 miles away)
281-912-3264
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Ryan Goldstein is a Gastroenterologist in Houston, Texas. Dr. Goldstein is rated as an Advanced provider by MediFind in the treatment of Anal Fissure. His top areas of expertise are Berdon Syndrome, Anal Fissure, Intestinal Cancer, and Familial Adenomatous Polyposis.

Advanced in Anal Fissure
Dr. Moazzam Sana
Gastroenterology
Advanced in Anal Fissure
Dr. Moazzam Sana
Gastroenterology

Texas Digestive Disease Consultants, PLLC

4100 S Shepherd Dr, 
Houston, TX 
 (2.3 miles away)
713-795-4444
Languages Spoken:
English
See accepted insurances

Moazzam Sana is a Gastroenterologist in Houston, Texas. Dr. Sana is rated as an Advanced provider by MediFind in the treatment of Anal Fissure. His top areas of expertise are Gastroesophageal Reflux Disease (GERD), Gas Bloat Syndrome, Familial Adenomatous Polyposis, Endoscopy, and Gastrostomy.

Advanced in Anal Fissure
Dr. Nikhil Inamdar
Gastroenterology
Advanced in Anal Fissure
Dr. Nikhil Inamdar
Gastroenterology

Texas Digestive Disease Consultants, PLLC

18220 State Hwy 249, Suite 290, 
Houston, TX 
 (20.6 miles away)
281-897-8866
Languages Spoken:
English
See accepted insurances

Nikhil Inamdar is a Gastroenterologist in Houston, Texas. Dr. Inamdar is rated as a Distinguished provider by MediFind in the treatment of Anal Fissure. His top areas of expertise are Gastroesophageal Reflux Disease (GERD), Diverticular Disease, Non-Alcoholic Fatty Liver Disease, Gastrectomy, and Endoscopy.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Hou's expertise for a condition
ConditionClose
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile